Dimension Therapeutics Stock Price, News & Analysis (NASDAQ:DMTX)

$5.95 0.00 (0.00 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$5.95
Today's Range$5.95 - $5.95
52-Week Range$1.05 - $6.10
VolumeN/A
Average Volume150,214 shs
Market Capitalization$149.06 million
P/E Ratio-2.67
Dividend YieldN/A
BetaN/A

About Dimension Therapeutics (NASDAQ:DMTX)

Dimension Therapeutics logoDimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company's gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company's lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.

Receive DMTX News and Ratings via Email

Sign-up to receive the latest news and ratings for DMTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:DMTX
CUSIPN/A
Phone+1-617-4010011

Debt

Debt-to-Equity Ratio0.14%
Current Ratio2.01%
Quick Ratio3.33%

Price-To-Earnings

Trailing P/E Ratio-2.66816143497758
Forward P/E Ratio-2.99
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.47 million
Price / Sales13.08
Cash FlowN/A
Price / CashN/A
Book Value$0.80 per share
Price / Book7.44

Profitability

Trailing EPS($2.23)
Net Income$-49,000,000.00
Net Margins-378.28%
Return on Equity-240.95%
Return on Assets-118.91%

Miscellaneous

Employees74
Outstanding Shares25,210,000

Dimension Therapeutics (NASDAQ:DMTX) Frequently Asked Questions

What is Dimension Therapeutics' stock symbol?

Dimension Therapeutics trades on the NASDAQ under the ticker symbol "DMTX."

How were Dimension Therapeutics' earnings last quarter?

Dimension Therapeutics Inc (NASDAQ:DMTX) posted its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.20. The biotechnology company had revenue of $4.48 million for the quarter. Dimension Therapeutics had a negative return on equity of 240.95% and a negative net margin of 378.28%. View Dimension Therapeutics' Earnings History.

Where is Dimension Therapeutics' stock going? Where will Dimension Therapeutics' stock price be in 2018?

6 equities research analysts have issued 1-year price targets for Dimension Therapeutics' shares. Their forecasts range from $3.00 to $7.00. On average, they expect Dimension Therapeutics' share price to reach $5.08 in the next year. View Analyst Ratings for Dimension Therapeutics.

What are Wall Street analysts saying about Dimension Therapeutics stock?

Here are some recent quotes from research analysts about Dimension Therapeutics stock:

  • 1. Chardan Capital analysts commented, "We believe 2017 has been an even better year fundamentally, on the expansion of breakthrough results, the first 3 GT approvals in the US, sector late-stage momentum, sound safety, and other considerations below. We now make uniQure (Buy) a Chardan Top Pick for 2018 and a Chardan Top Pick in Gene Therapy for 2018." (12/22/2017)
  • 2. According to Zacks Investment Research, "Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts. " (7/10/2017)
  • 3. Cantor Fitzgerald analysts commented, "We are lowering our rating to Neutral from Overweight and price target to $3 from $32, following initial results from Dimension's Phase 1/2 Study with DTX101 in Hemophilia B. Results highlighted that DTX101 will require additional optimization to be competitive with currently ongoing Hemophilia B gene therapy programs. While DTX101 was able to achieve meaningful peak FIX levels, these levels declined significantly in all patients. In addition, five of six patients demonstrated elevated levels of ALTs, which could hinder the company's ability to dose higher. Seeing the need for additional optimization for the hemophilia B program, we are moving to the sidelines and adjusting our price target." (1/31/2017)

Who are some of Dimension Therapeutics' key competitors?

Who are Dimension Therapeutics' key executives?

Dimension Therapeutics' management team includes the folowing people:

  • Georges Gemayel Ph.D., Chairman of the Board (Age 56)
  • Annalisa M. Jenkins, President, Chief Executive Officer, Director (Age 52)
  • Mary T. Thistle, Principal Financial and Accounting Officer, Chief Operating Officer (Age 57)
  • Samuel C. Wadsworth Ph.D., Chief Scientific Officer (Age 68)
  • Eric Crombez M.D., Chief Medical Officer (Age 44)
  • John Hohneker, Director (Age 57)
  • Alan B. Colowick M.D., Independent Director (Age 54)
  • Michael Dybbs Ph.D., Independent Director (Age 42)
  • George V. Migausky, Independent Director (Age 62)
  • Arlene M. Morris, Independent Director (Age 65)

How do I buy Dimension Therapeutics stock?

Shares of Dimension Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dimension Therapeutics' stock price today?

One share of Dimension Therapeutics stock can currently be purchased for approximately $5.95.

How big of a company is Dimension Therapeutics?

Dimension Therapeutics has a market capitalization of $149.06 million and generates $11.47 million in revenue each year. The biotechnology company earns $-49,000,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Dimension Therapeutics employs 74 workers across the globe.

How can I contact Dimension Therapeutics?

Dimension Therapeutics' mailing address is 840 Memorial Dr Ste 4, CAMBRIDGE, MA 02139-3771, United States. The biotechnology company can be reached via phone at +1-617-4010011.


MarketBeat Community Rating for Dimension Therapeutics (DMTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  272
MarketBeat's community ratings are surveys of what our community members think about Dimension Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dimension Therapeutics (NASDAQ:DMTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.172.172.40
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.08$5.08$5.08$6.70
Price Target Upside: 14.59% downside13.86% downside13.86% downside396.30% upside

Dimension Therapeutics (NASDAQ:DMTX) Consensus Price Target History

Price Target History for Dimension Therapeutics (NASDAQ:DMTX)

Dimension Therapeutics (NASDAQ:DMTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/22/2017Chardan CapitalReiterated RatingBuyLowView Rating Details
10/3/2017Wells Fargo & CoDowngradeOutperform -> Market Perform$9.00 -> $6.00LowView Rating Details
10/3/2017CitigroupUpgradeSell -> Neutral$5.50 -> $6.00MediumView Rating Details
8/30/2017Canaccord GenuityDowngradeBuy -> Hold$12.00 -> $3.41LowView Rating Details
6/10/2017Cantor FitzgeraldSet Price TargetHold$3.00HighView Rating Details
2/2/2017Jefferies GroupReiterated RatingBuy$7.00N/AView Rating Details
3/30/2016Goldman Sachs GroupDowngradeBuy -> Neutral$10.00N/AView Rating Details
(Data available from 1/20/2016 forward)

Earnings

Dimension Therapeutics (NASDAQ:DMTX) Earnings History and Estimates Chart

Earnings by Quarter for Dimension Therapeutics (NASDAQ:DMTX)

Dimension Therapeutics (NASDAQ DMTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.48)($0.68)$4.48 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.49)($0.49)$4.37 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.52)($0.54)$3.62 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.56)($0.53)$3.04 million$4.10 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.56)($0.58)$2.37 million$2.76 millionViewN/AView Earnings Details
8/11/2016Q2 2016($0.43)($0.49)$2.21 million$2.37 millionViewN/AView Earnings Details
5/12/2016Q116($0.57)($0.38)$2.24 million$2.21 millionViewN/AView Earnings Details
3/24/2016Q4 2015($0.38)($0.45)$1.70 million$2.35 millionViewN/AView Earnings Details
12/4/2015Q3 2015($0.35)($2.73)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Dimension Therapeutics (NASDAQ:DMTX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.99 EPS
Next Year EPS Consensus Estimate: $-1.5 EPS

Dividends

Dividend History for Dimension Therapeutics (NASDAQ:DMTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Dimension Therapeutics (NASDAQ DMTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.18%
Institutional Ownership Percentage: 70.33%
Insider Trades by Quarter for Dimension Therapeutics (NASDAQ:DMTX)
Insider Trades by Quarter for Dimension Therapeutics (NASDAQ:DMTX)

Dimension Therapeutics (NASDAQ DMTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/7/2016K. Reed ClarkSVPSell5,000$10.00$50,000.005,000View SEC Filing  
10/27/2015Rishi GuptaDirectorBuy200,000$13.00$2,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dimension Therapeutics (NASDAQ DMTX) News Headlines

Source:
DateHeadline
Financial Comparison: Dimension Therapeutics (DMTX) and Capricor Therapeutics (CAPR)Financial Comparison: Dimension Therapeutics (DMTX) and Capricor Therapeutics (CAPR)
www.americanbankingnews.com - January 20 at 7:50 PM
Dimension Therapeutics Inc (DMTX) Given Consensus Recommendation of "Hold" by AnalystsDimension Therapeutics Inc (DMTX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - January 19 at 5:52 AM
Dimension Therapeutics Inc (DMTX) Given Consensus Rating of "Hold" by AnalystsDimension Therapeutics Inc (DMTX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 25 at 5:10 AM
Dimension Therapeutics (DMTX) Buy Rating Reaffirmed at Chardan CapitalDimension Therapeutics' (DMTX) Buy Rating Reaffirmed at Chardan Capital
www.americanbankingnews.com - December 22 at 8:36 AM
Analyzing Dimension Therapeutics (DMTX) & Its RivalsAnalyzing Dimension Therapeutics (DMTX) & Its Rivals
www.americanbankingnews.com - December 18 at 7:22 PM
Dimension Therapeutics, Inc. (DMTX) Given Consensus Rating of "Hold" by AnalystsDimension Therapeutics, Inc. (DMTX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - November 30 at 8:54 AM
Reviewing Dimension Therapeutics (DMTX) & Its PeersReviewing Dimension Therapeutics (DMTX) & Its Peers
www.americanbankingnews.com - November 24 at 9:34 AM
Should You Buy Dimension Therapeutics Inc (DMTX) At $5.95?Should You Buy Dimension Therapeutics Inc (DMTX) At $5.95?
finance.yahoo.com - November 16 at 1:31 PM
Dimension Therapeutics, Inc. (DMTX) Issues Quarterly  Earnings ResultsDimension Therapeutics, Inc. (DMTX) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 8 at 4:44 PM
Dimension Therapeutics, Inc. (DMTX) Given Average Rating of "Hold" by BrokeragesDimension Therapeutics, Inc. (DMTX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 5 at 5:52 AM
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Dimension Therapeutics, Inc.SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Dimension Therapeutics, Inc.
finance.yahoo.com - November 1 at 12:11 AM
Ultragenyx Pharma (RARE), Dimension (DMTX) Announce Expiration of HSR Waiting Period for Ultragenyxs Acquisition of DimensionUltragenyx Pharma (RARE), Dimension (DMTX) Announce Expiration of HSR Waiting Period for Ultragenyx's Acquisition of Dimension
www.streetinsider.com - October 26 at 2:00 PM
Ultragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx’s Acquisition of DimensionUltragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx’s Acquisition of Dimension
finance.yahoo.com - October 26 at 2:00 PM
WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX ShareholdersWEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders
finance.yahoo.com - October 13 at 6:31 PM
SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of Dimension Therapeutics, Inc. - DMTXSHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of Dimension Therapeutics, Inc. - DMTX
finance.yahoo.com - October 13 at 6:31 PM
Dimension Therapeutics, Inc. (DMTX) Receives Average Recommendation of "Hold" from AnalystsDimension Therapeutics, Inc. (DMTX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 11 at 8:49 AM
Harwood Feffer LLP Announces Investigation of Dimension Therapeutics, Inc.Harwood Feffer LLP Announces Investigation of Dimension Therapeutics, Inc.
finance.yahoo.com - October 5 at 5:08 PM
Dimension (DMTX) Alert: Johnson Fistel Investigates Proposed Sale of Dimension Therapeutics, Inc.; Are Shareholders Getting a Fair Price?Dimension (DMTX) Alert: Johnson Fistel Investigates Proposed Sale of Dimension Therapeutics, Inc.; Are Shareholders Getting a Fair Price?
www.prnewswire.com - October 3 at 5:50 PM
​After bidding war, North Bay drug maker snags gene therapy company for $151 million​After bidding war, North Bay drug maker snags gene therapy company for $151 million
finance.yahoo.com - October 3 at 5:50 PM
Dimension Therapeutics, Inc. (DMTX) Downgraded to Market Perform at Wells Fargo & CompanyDimension Therapeutics, Inc. (DMTX) Downgraded to Market Perform at Wells Fargo & Company
www.americanbankingnews.com - October 3 at 4:40 PM
VICL Soars After-hours, DMTX Deems RARE Bid Superior, MDXG On WatchVICL Soars After-hours, DMTX Deems RARE Bid Superior, MDXG On Watch
www.rttnews.com - October 3 at 8:49 AM
Ultragenyx To Acquire Dimension Therapeutics In Approx. $151 Mln DealUltragenyx To Acquire Dimension Therapeutics In Approx. $151 Mln Deal
www.nasdaq.com - October 3 at 8:49 AM
Ultragenyx to Acquire Dimension TherapeuticsUltragenyx to Acquire Dimension Therapeutics
finance.yahoo.com - October 3 at 8:49 AM
Dimension Therapeutics, Inc. (DMTX) Cut to Sell at Citigroup Inc.Dimension Therapeutics, Inc. (DMTX) Cut to Sell at Citigroup Inc.
www.americanbankingnews.com - September 24 at 1:00 PM
Dimension Board of Directors Determines Proposal from Ultragenyx ...Dimension Board of Directors Determines Proposal from Ultragenyx ...
www.nasdaq.com - September 21 at 5:59 PM
Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”
finance.yahoo.com - September 19 at 11:01 PM
Ultragenyx Proposes To Buy Dimension Therapeutics For $5.50/shr In CashUltragenyx Proposes To Buy Dimension Therapeutics For $5.50/shr In Cash
www.rttnews.com - September 19 at 1:24 AM
Will Dimension Therapeutics Take the New and Bigger Buyout Offer?Will Dimension Therapeutics Take the New and Bigger Buyout Offer?
247wallst.com - September 19 at 1:24 AM
Ultragenyx Proposes to Acquire Dimension Therapeutics for $5.50 Per Share in CashUltragenyx Proposes to Acquire Dimension Therapeutics for $5.50 Per Share in Cash
finance.yahoo.com - September 18 at 3:20 PM
Ultragenyx Makes Bid for Dimension Therapeutics - Biotech MoversUltragenyx Makes Bid for Dimension Therapeutics - Biotech Movers
finance.yahoo.com - September 18 at 3:20 PM
UPDATED: Dimension Therapeutics shares surge 38% on Ultragenyx bidUPDATED: Dimension Therapeutics shares surge 38% on Ultragenyx bid
finance.yahoo.com - September 18 at 3:20 PM
Dimension Confirms Receipt of Unsolicited Proposal from UltragenyxDimension Confirms Receipt of Unsolicited Proposal from Ultragenyx
finance.yahoo.com - September 18 at 3:20 PM
Dimension Therapeutics, Inc. (DMTX) Given Consensus Recommendation of "Hold" by AnalystsDimension Therapeutics, Inc. (DMTX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 16 at 9:10 AM
Dimension Therapeutics, Inc. (DMTX) Expected to Announce Earnings of -$0.49 Per ShareDimension Therapeutics, Inc. (DMTX) Expected to Announce Earnings of -$0.49 Per Share
www.americanbankingnews.com - September 15 at 4:28 AM
Dimension Therapeutics (DMTX) & Madrigal Pharmaceuticals (MDGL) Critical AnalysisDimension Therapeutics (DMTX) & Madrigal Pharmaceuticals (MDGL) Critical Analysis
www.americanbankingnews.com - September 6 at 12:16 AM
OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of DirectorsOncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors
finance.yahoo.com - September 5 at 7:29 PM
ETFs with exposure to Dimension Therapeutics, Inc. : August 31, 2017ETFs with exposure to Dimension Therapeutics, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 10:12 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Dimension Therapeutics, Inc. - DMTXSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Dimension Therapeutics, Inc. - DMTX
finance.yahoo.com - August 31 at 10:12 PM
Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) DeficiencyDimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency
finance.yahoo.com - August 31 at 5:11 PM
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Shareholders to Contact the Firm for Additional InformationINVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Shareholders to Contact the Firm for Additional Information
finance.yahoo.com - August 31 at 5:11 PM
Canaccord Genuity Reaffirms Hold Rating for Dimension Therapeutics, Inc. (DMTX)Canaccord Genuity Reaffirms Hold Rating for Dimension Therapeutics, Inc. (DMTX)
www.americanbankingnews.com - August 30 at 10:42 AM
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Dimension Therapeutics, Inc. - DMTXSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Dimension Therapeutics, Inc. - DMTX
finance.yahoo.com - August 28 at 10:45 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Dimension Therapeutics, Inc. to REGENXBIO Inc. is Fair to ShareholdersSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Dimension Therapeutics, Inc. to REGENXBIO Inc. is Fair to Shareholders
finance.yahoo.com - August 26 at 12:32 AM
Regenxbio Buying Dimension Therapeutics for $3.41 Per ShareRegenxbio Buying Dimension Therapeutics for $3.41 Per Share
www.baystreet.ca - August 25 at 7:28 PM
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Investors to Contact the Firm for Additional ...SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Investors to Contact the Firm for Additional ...
www.businesswire.com - August 25 at 7:28 PM
Dimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017Dimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 25 at 7:28 PM
Rockville biotech buys Cambridge gene therapy firm for $86MRockville biotech buys Cambridge gene therapy firm for $86M
finance.yahoo.com - August 25 at 7:28 PM
DIMENSION THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BuyoutDIMENSION THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
finance.yahoo.com - August 25 at 7:28 PM
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Investors to Contact the Firm for Additional InformationSHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Investors to Contact the Firm for Additional Information
finance.yahoo.com - August 25 at 7:28 PM
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dimension Therapeutics, Inc.ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dimension Therapeutics, Inc.
finance.yahoo.com - August 25 at 7:28 PM

SEC Filings

Dimension Therapeutics (NASDAQ:DMTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dimension Therapeutics (NASDAQ:DMTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dimension Therapeutics (NASDAQ DMTX) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.